Evofem Biosciences to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference

Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) announced its participation in the H.C. Wainwright BIOCONNECT 2021 Virtual Conference on December 21, 2020. CEO Saundra Pelletier will discuss the commercialization of Phexxi®, the first FDA-approved hormone-free contraceptive vaginal gel, and provide updates on the ongoing EVOGUARD Phase 3 trial. This trial evaluates EVO100 in preventing chlamydia and gonorrhea. The presentation will be available for on-demand listening starting January 11, 2021, at 6:00 AM Eastern on the company's website under the Events and Presentations tab.

SAN DIEGO, Dec. 21, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.

Evofem's CEO, Saundra  Pelletier, will provide updates on the commercialization of Phexxi® (lactic acid, citric acid and potassium bitartrate), the first and only FDA-approved, hormone free contraceptive vaginal gel, and the pivotal Phase 3 EVOGUARD trial, which is evaluating EVO100 for the prevention of chlamydia and gonorrhea in women and currently enrolling subjects at study centers across the U.S. 

The presentation will be available for on-demand listening  beginning Monday, January 11, 2021, at 6:00 AM Eastern Time on the Investors section of the Evofem Biosciences website at www.evofem.com, under the Events and Presentations tab.

About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, 'EVOGUARD,' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. For more information, please visit www.evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775

Media Contact
Ellen Thomas
Evofem Biosciences, Inc.
ethomas@evofem.com
Mobile: (718) 490-3248

View original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-the-hc-wainwright-bioconnect-2021-virtual-conference-301196515.html

SOURCE Evofem Biosciences, Inc.

FAQ

When will Evofem Biosciences present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference?

Evofem Biosciences will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference on December 21, 2020.

What is Phexxi and why is it significant for Evofem Biosciences?

Phexxi® is the first FDA-approved hormone-free contraceptive vaginal gel, marking a significant innovation in women's reproductive health.

What does the EVOGUARD trial aim to achieve for Evofem Biosciences?

The EVOGUARD trial is evaluating EVO100 for the prevention of chlamydia and gonorrhea in women.

When will the on-demand presentation be available after the conference?

The on-demand presentation will be available starting January 11, 2021, at 6:00 AM Eastern Time.

Where can I find more information about Evofem Biosciences?

More information can be found on the Evofem Biosciences website at www.evofem.com.